Cancer crusade: Stony Brook-based Applied DNA Sciences and Italian biopharma EvviVax are one step closer to a bona fide DNA-based cancer vaccine.
By GREGORY ZELLER //
New vaccines produced in part by a progressive Long Island biotech could significantly increase the efficacy of existing cancer treatments.
The potential breakthrough – detailed this month in a manuscript posted on bioRxiv, an open-access preprint repository for the biological sciences hosted by Cold Spring Harbor Laboratory – comes courtesy of Stony Brook-based Applied DNA Sciences and EvviVax, the local innovator’s Italy-based program partner.
